The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial

Masurekar, A, Fong, C, Hussain, A et al. (7 more authors) (2014) The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial. Blood Cancer Journal, 4. e203. ISSN 2044-5385

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2014 Macmillan Publishers Limited. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Dates:
  • Published: 25 April 2014
  • Published (online): 25 April 2014
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 24 Sep 2021 15:04
Last Modified: 24 Sep 2021 15:04
Status: Published
Publisher: Springer Nature
Identification Number: 10.1038/bcj.2014.26
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)